US 12,358,971 B2
Arena virus monoclonal antibodies and uses
Luis M. Branco, Germantown, MD (US); Robert F. Garry, New Orleans, LA (US); James E. Robinson, New Orleans, LA (US); Erica O. Saphire, La Jolla, CA (US); Kathryn M. Hastie, La Jolla, CA (US); and Thomas W. Geisbert, Albany, TX (US)
Assigned to The Administrators of the Tulane Educational Fund, New Orleans, LA (US); The Boad of Regents of the University of Texas System, Austin, TX (US); The Scripps Resesrch Institute, La Jolla, CA (US); and Zalgen Labs, LLC, Germantown, MD (US)
Filed by THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, New Orleans, LA (US); THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA (US); THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US); and ZALGEN LABS, LLC, Germantown, MD (US)
Filed on Dec. 21, 2023, as Appl. No. 18/392,147.
Application 18/392,147 is a division of application No. 17/520,338, filed on Nov. 5, 2021, abandoned.
Application 17/520,338 is a division of application No. 16/466,544, granted, now 11,198,723, issued on Dec. 14, 2021, previously published as PCT/US2017/064744, filed on Dec. 5, 2017.
Claims priority of provisional application 62/430,225, filed on Dec. 5, 2016.
Prior Publication US 2024/0352095 A1, Oct. 24, 2024
Int. Cl. C07K 16/10 (2006.01); A61P 31/14 (2006.01)
CPC C07K 16/10 (2013.01) [A61P 31/14 (2018.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C12N 2760/10011 (2013.01)] 20 Claims
 
1. An antigen-binding composition comprising a combination of three recombinant monoclonal neutralizing antibodies or neutralizing antigen-binding antibody fragments thereof, which are specific to Lassa virus glycoprotein, wherein the composition comprises:
a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a VH CDR1 of SEQ ID NO: 83, a VH CDR2 of SEQ ID NO: 84, a VH CDR3 of SEQ ID NO: 85, a VL CDR1 of SEQ ID NO: 125, a VL CDR2 of sequence Gly Ala Ser, and a VL CDR3 of SEQ ID NO: 126;
a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a VH CDR1 of SEQ ID NO: 92, a VH CDR2 of SEQ ID NO: 93, a VH CDR3 of SEQ ID NO: 94, a VL CDR1 of SEQ ID NO: 131, a VL CDR2 of sequence Glu Val Ser, and a VL CDR3 of SEQ ID NO: 132; and
a recombinant human monoclonal antibody or an antigen-binding antibody fragment thereof comprising a VH CDR1 of SEQ ID NO: 98, a VH CDR2 of SEQ ID NO: 99, a VH CDR3 of SEQ ID NO: 100, a VL CDR1 of SEQ ID NO: 135, a VL CDR2 of sequence Gly Ala Ser, and a VL CDR3 of SEQ ID NO: 136.